vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Jack Henry & Associates (JKHY). Click either name above to swap in a different company.
Jack Henry & Associates is the larger business by last-quarter revenue ($619.3M vs $598.7M, roughly 1.0× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 20.1%, a 20.7% gap on every dollar of revenue. On growth, Jack Henry & Associates posted the faster year-over-year revenue change (7.9% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $131.4M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 7.2%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Jack Henry and Associates, also known as Jack Henry is an American company founded in 1976 and devoted to financial technology and payment processing services, mostly for community banks and credit unions. They assist regional banks and credit unions to control risk, make regulatory filings and add or improve their online banking services. Jack Henry stock trades on the NASDAQ exchange under the symbol JKHY, and is also part of the S&P 400 for mid-size American companies.
EXEL vs JKHY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $619.3M |
| Net Profit | $244.5M | $124.7M |
| Gross Margin | 95.6% | 43.3% |
| Operating Margin | 39.3% | 25.7% |
| Net Margin | 40.8% | 20.1% |
| Revenue YoY | 5.6% | 7.9% |
| Net Profit YoY | 74.8% | 27.4% |
| EPS (diluted) | $0.89 | $1.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $619.3M | ||
| Q3 25 | $568.3M | $644.7M | ||
| Q2 25 | $555.4M | $615.4M | ||
| Q1 25 | $566.8M | $585.1M | ||
| Q4 24 | — | $573.8M | ||
| Q3 24 | $539.5M | $601.0M | ||
| Q2 24 | $637.2M | $559.9M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $124.7M | ||
| Q3 25 | $184.8M | $144.0M | ||
| Q2 25 | $159.6M | $127.6M | ||
| Q1 25 | $139.9M | $111.1M | ||
| Q4 24 | — | $97.8M | ||
| Q3 24 | $118.0M | $119.2M | ||
| Q2 24 | $226.1M | $101.1M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 43.3% | ||
| Q3 25 | 96.6% | 45.9% | ||
| Q2 25 | 96.5% | 44.1% | ||
| Q1 25 | 96.5% | 41.8% | ||
| Q4 24 | — | 42.0% | ||
| Q3 24 | 96.8% | 42.9% | ||
| Q2 24 | 97.2% | 41.5% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 25.7% | ||
| Q3 25 | 37.6% | 28.5% | ||
| Q2 25 | 33.6% | 25.3% | ||
| Q1 25 | 28.8% | 23.7% | ||
| Q4 24 | — | 21.4% | ||
| Q3 24 | 25.2% | 25.2% | ||
| Q2 24 | 43.3% | 22.4% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 20.1% | ||
| Q3 25 | 32.5% | 22.3% | ||
| Q2 25 | 28.7% | 20.7% | ||
| Q1 25 | 24.7% | 19.0% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | 21.9% | 19.8% | ||
| Q2 24 | 35.5% | 18.1% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.72 | ||
| Q3 25 | $0.65 | $1.97 | ||
| Q2 25 | $0.55 | $1.75 | ||
| Q1 25 | $0.47 | $1.52 | ||
| Q4 24 | — | $1.34 | ||
| Q3 24 | $0.40 | $1.63 | ||
| Q2 24 | $0.77 | $1.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $28.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $2.2B |
| Total Assets | $2.8B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $28.2M | ||
| Q3 25 | $791.1M | $36.2M | ||
| Q2 25 | $1.0B | $102.0M | ||
| Q1 25 | $1.1B | $39.9M | ||
| Q4 24 | — | $25.7M | ||
| Q3 24 | $1.2B | $43.2M | ||
| Q2 24 | $1.0B | $38.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $60.0M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $2.3B | $1.9B | ||
| Q2 24 | $2.1B | $1.8B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $3.1B | ||
| Q3 25 | $2.7B | $3.0B | ||
| Q2 25 | $2.8B | $3.0B | ||
| Q1 25 | $2.9B | $2.9B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $3.0B | $2.9B | ||
| Q2 24 | $2.8B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $152.7M |
| Free Cash FlowOCF − Capex | $332.4M | $131.4M |
| FCF MarginFCF / Revenue | 55.5% | 21.2% |
| Capex IntensityCapex / Revenue | 0.2% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.36× | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $654.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $152.7M | ||
| Q3 25 | $49.0M | $120.6M | ||
| Q2 25 | $211.4M | $327.1M | ||
| Q1 25 | $240.3M | $107.8M | ||
| Q4 24 | — | $89.6M | ||
| Q3 24 | $271.3M | $116.9M | ||
| Q2 24 | $119.5M | $231.8M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $131.4M | ||
| Q3 25 | $46.2M | $111.7M | ||
| Q2 25 | $208.5M | $314.9M | ||
| Q1 25 | $236.3M | $96.1M | ||
| Q4 24 | — | $73.0M | ||
| Q3 24 | $263.1M | $104.1M | ||
| Q2 24 | $113.0M | $208.0M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 21.2% | ||
| Q3 25 | 8.1% | 17.3% | ||
| Q2 25 | 37.5% | 51.2% | ||
| Q1 25 | 41.7% | 16.4% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | 48.8% | 17.3% | ||
| Q2 24 | 17.7% | 37.2% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 3.4% | ||
| Q3 25 | 0.5% | 1.4% | ||
| Q2 25 | 0.5% | 2.0% | ||
| Q1 25 | 0.7% | 2.0% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | 1.5% | 2.1% | ||
| Q2 24 | 1.0% | 4.2% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.22× | ||
| Q3 25 | 0.27× | 0.84× | ||
| Q2 25 | 1.32× | 2.56× | ||
| Q1 25 | 1.72× | 0.97× | ||
| Q4 24 | — | 0.92× | ||
| Q3 24 | 2.30× | 0.98× | ||
| Q2 24 | 0.53× | 2.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
JKHY
| Processing | $273.5M | 44% |
| Private Public Cloud | $202.7M | 33% |
| On Premise Support | $79.0M | 13% |
| Product Deliveryand Service | $64.1M | 10% |
